As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
8 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:
8 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -8.23 -8.23 |
13%
13%
|
Net Profit | -7.69 -7.69 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Lawyer Joseph F on April 23, 2020 and is headquartered in Lakeway, TX.
Head office | United States |
CEO | Richard Cunningham |
Employees | 3 |
Founded | 2020 |
Website | www.anebulo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.